Based on these results, we conclude that this novel derivative of sulfonamide (3D) induces 1) ROS-mediated apoptosis; 2) induction of p53 and Bax; 3) inhibition of Bcl2 and BclxL; and 4) cytochrome c release, PARP cleavage and activation of caspases. Our findings further demonstrate that 3D inhibits the JAK2–STAT3 signaling pathway and target genes, which may provide a mechanistic basis for this compound. 3D-mediated inhibition of STAT3 activation also sensitizes Dox efficacy in CRC. Hence, 3D-mediated inhibition of STAT3 activation and induction of ROS-dependent apoptosis suggest that 3D is an attractive candidate for further investigation as a potential anticancer agent.


Continue Reading

The authors are grateful to the Deanship of Scientific Research, King Saud University for funding through Vice Deanship of Scientific Research Chairs.


The authors report no conflicts of interest in this work.

Omar Al-Obeed,1 Mansoor-Ali Vaali-Mohammed,Wagdy M. Eldehna,2 Khayal Al-Khayal,1 Amer Mahmood,3 Hatem A. Abdel-Aziz,4 Ahmed Zubaidi,1 Ahmed Alafeefy,5 Maha Abdulla,1 Rehan Ahmad1

1Colorectal Research Chair, Department of Surgery, King Khaled University Hospital, College of Medicine, King Saud University, Riyadh, Saudi Arabia; 2Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt; 3Stem Cell Unit, Department of Anatomy, College of Medicine, King Saud University, Riyadh, Saudi Arabia; 4Department of Applied Organic Chemistry, National Research Center, Cairo, Egypt; 5Department of Chemistry, Kulliyyah of Science, International Islamic University, Kuantan, Malaysia 


1. De Rosa M, Pace U, Rega D, et al. Genetics, diagnosis and management of colorectal cancer. Oncol Rep. 2015;34(3):1087–1096.

2. Strum BW. Colorectal adenomas. N Engl J Med. 2016;374(11):1065–1075.

3. Pancione M, Remo A, Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Patholog Res Int. 2012;2012:509348.

4. Ewing I, Hurley JJ, Josephides E, Millar A. The molecular genetics of colorectal cancer. Frontline Gastroenterol. 2014;5:26–30.

5. Jawad N, Direkze N, Leedham SJ. Inflammatory bowel disease and colon cancer. Recent Results Cancer Res. 2011;185:99–115.

6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.

7. Andersen NN, Jess T. Has the risk of colorectal cancer in inflammatory bowel disease decreased? World J Gastroenterol. 2013;19(43):7561–7568.

8. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525–532.

9. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002;8(4):945–954.

10. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000;19(21):2468–2473.

11. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 2000;19(56):6613–6626.

12. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19(21):2474–2488.

13. Chiarle R, Simmons WJ, Cai H, et al. STAT3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005;11(6):623–629.

14. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting STAT3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;11(12):1314–1321.

15. Darnell JE. Validating STAT3 in cancer therapy. Nat Med. 2005;11(6):595–596.

16. Xiong H, Zhang ZG, Tian XQ, et al. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia. 2008;10(3):287–297.

17. Lin Q, Lai R, Chirieac LR, et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumours and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol. 2005;167(4):969–980.

18. Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature. 2000;407(6805):810–816.

19. Alafeefy AM, Ahmad R, Abdulla M, et al. Development of certain new 2-substituted-quinazolin-4-yl-aminobenzenesulfonamide as potential antitumor agents. Eur J Med Chem. 2016;109:247–253.

20. Al-Khayal K, Alafeefy A, Vaali-Mohammed MA, et al. Novel derivative of aminobenzenesulfonamide (3c) induces apoptosis in colorectal cancer cells through ROS generation and inhibits cell migration. BMC Cancer. 2017;17:4.

21. Zhang X, Wang X, Wu T, et al. Isoliensinine induces apoptosis in triple-negative human breast cancer through ROS generation and p38 MAPK/JNK activation. Sci Rep. 2015;5:12579.

22. Subramani R, Gonzalez E, Arumugam A, et al. Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition. Sci Rep. 2016;6:19819.

23. Sreevalsan S, Safe S. Reactive oxygen species and colorectal cancer. Curr Colorectal Cancer Rep. 2013;9(4):350–357.

24. Trachootham D, Alexandr J, Huang P. Targeting cancer cells by ROS-mediated mechanism: a radical therapeutic approach. Nat Rev Drug Discov. 2009;8(7):579–591.

25. Gomez-Lazaro M, Galindo MF, de Melero-Fernandez Mera RM, et al. Reactive oxygen species and p38 mitogen-activated protein kinase activate Bax to induce mitochondrial cytochrome c release and apoptosis in response to malonate. Mol Pharmacol. 2007;71(3):736–743.

26. Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. Intermediacy of H2O2 and p53-dependent pathway. J Biol Chem. 2004;279(24):25535–25543.

27. Zhu S, Li T, Tan J, et al. Bax is essential for death receptor-mediated apoptosis in human colon cancer cells. Cancer Biother Radiopharm. 2012;27(9):577–581.

28. Cherbonnel-Lasserre C, Dosanjh ML. Suppression of apoptosis by overexpression of Bcl2 or BclxL promotes survival and mutagenesis after oxidative damage. Biochimie. 1997;79(9–10):613–617.

29. Bonnotte B, Favre N, Moutet M, et al. Bcl2-mediated inhibition of apoptosis prevents immunogenicity and restores tumorigenicity of spontaneously regressive tumors. J Immunol. 1998;161(13):1433–1438.

Source: OncoTargets and Therapy
Originally published June 5, 2018.